SII said it will be able to manufacture and supply 10 crore Covishield doses in June while also manufacturing Novavax.
The development and commercialisation pact between Novavax and SII excludes major upper-middle and high-income countries as they retain the rights
A single-dose vaccine is a big advantage when most countries are struggling to get shots in arms more quickly.
The company is aiming to launch the vaccine being produced in collaboration with American vaccine development company Novavax by June 2021, SII CEO Adar Poonawalla said
Almost two billion doses of candidate vaccines have been secured for the Covax facility, created by the UN health agency, to ensure fair access
Phase 3 of the COVISHIELD human trials will involve 1600 participants.
In order to reduce the premature deaths and other irreversible health issues caused due to COVID-19, nineteen scientists from around the world have proposed a new three-phase plan called the Fair Priority Model for the distribution of the vaccine
This is the biggest grant till now from the White House programme aimed at speeding up access to COVID-19 vaccines and treatments
COVID-19 Vaccine Update: Novavax starts phase I/II clinical trials, here's all you need to know about the vaccine
Named NVX‑CoV2373, Novavax’s vaccine is created using recombinant protein nanoparticle technology.